ABCL / AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2023 Results Conference Call November 2, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & more_horizontal

GRPN, NRIX, RNLX, ABCL and SMAR have been added to the Zacks Rank #1 (Strong Buy) List on October 26, 2023. more_horizontal

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023. more_horizontal

Artificial intelligence ( AI ) will have a profound impact on the medical industry, where it could help accelerate drug discovery and patient treatmen more_horizontal

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & C more_horizontal

The average of price targets set by Wall Street analysts indicates a potential upside of 242.1% in AbCellera Biologics Inc. (ABCL). While the effectiv more_horizontal

AI is coming to biotech in a big way. From protein folding to drug screening, from studying cells to studying populations, the AI boom has long been a more_horizontal

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, more_horizontal